Laxmipriya Nampoothiri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Laxmipriya Nampoothiri has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Arpi Dey
Department of Biochemistry, Faculty of Science, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat, 390002, India
4 shared publications- Sarita Gupta
Department of Biochemistry, Faculty of Science, The Maharaja Sayajirao University of Baroda, Vadodara, India
4 shared publications Nirja Chaudhari
3 shared publicationsRadha Maharjan
Department of Biochemistry, Faculty of Science, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat, 390002, India
3 shared publicationsShivani Dhadhal
Department of Biochemistry, Faculty of Science, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat, 390002, India
2 shared publicationsA Jagannadha Rao
1 shared publication
Latest Publications
- 1 June 2021
- Published by Ukaaz Publications in Annals of Phytomedicine An International Journal
- Vol. 10 (1) , 78-85
Fruit juice of Garcinia indica Choisy modulates dyslipidemia and lipid metabolism in cafeteria diet based rat model
- 1 June 2021
- Published by Ukaaz Publications in Annals of Phytomedicine An International Journal
- Vol. 10 (1) , 78-85
Fruit juice of Garcinia indica Choisy modulates dyslipidemia and lipid metabolism in cafeteria diet based rat model
- Top Cited PapersOpen Access
- 11 April 2018
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 16 (1) , 1-13
GnRH dysregulation in polycystic ovarian syndrome (PCOS) is a manifestation of an altered neurotransmitter profile
GnRH is the master molecule of reproduction that is influenced by several intrinsic and extrinsic factors such as neurotransmitters and neuropeptides. Any alteration in these regulatory loops may result in reproductive-endocrine dysfunction such as the polycystic ovarian syndrome (PCOS). Although low dopaminergic tone has been associated with PCOS, the role of neurotransmitters in PCOS remains unknown. The present study was therefore aimed at understanding the status of GnRH regulatory neurotransmitters to decipher the neuroendocrine pathology in PCOS. PCOS was induced in rats by oral administration of letrozole (aromatase inhibitor). Following PCOS validation, animals were assessed for gonadotropin levels and their mRNA expression. Neurotrasnmitter status was evaluated by estimating their levels, their metabolism and their receptor expression in hypothalamus, pituitary, hippocampus and frontal cortex of PCOS rat model. We demonstrate that GnRH and LH inhibitory neurotransmitters – serotonin, dopamine, GABA and acetylcholine – are reduced while glutamate, a major stimulator of GnRH and LH release, is increased in the PCOS condition. Concomitant changes were observed for neurotransmitter metabolising enzymes and their receptors as well. Our results reveal that increased GnRH and LH pulsatility in PCOS condition likely result from the cumulative effect of altered GnRH stimulatory and inhibitory neurotransmitters in hypothalamic-pituitary centre. This, we hypothesise, is responsible for the depression and anxiety-like mood disorders commonly seen in PCOS women.
- 11 April 2018
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 16 (1) , 1-13
Top Cited PapersOpen AccessGnRH dysregulation in polycystic ovarian syndrome (PCOS) is a manifestation of an altered neurotransmitter profile
GnRH is the master molecule of reproduction that is influenced by several intrinsic and extrinsic factors such as neurotransmitters and neuropeptides. Any alteration in these regulatory loops may result in reproductive-endocrine dysfunction such as the polycystic ovarian syndrome (PCOS). Although low dopaminergic tone has been associated with PCOS, the role of neurotransmitters in PCOS remains unknown. The present study was therefore aimed at understanding the status of GnRH regulatory neurotransmitters to decipher the neuroendocrine pathology in PCOS. PCOS was induced in rats by oral administration of letrozole (aromatase inhibitor). Following PCOS validation, animals were assessed for gonadotropin levels and their mRNA expression. Neurotrasnmitter status was evaluated by estimating their levels, their metabolism and their receptor expression in hypothalamus, pituitary, hippocampus and frontal cortex of PCOS rat model. We demonstrate that GnRH and LH inhibitory neurotransmitters – serotonin, dopamine, GABA and acetylcholine – are reduced while glutamate, a major stimulator of GnRH and LH release, is increased in the PCOS condition. Concomitant changes were observed for neurotransmitter metabolising enzymes and their receptors as well. Our results reveal that increased GnRH and LH pulsatility in PCOS condition likely result from the cumulative effect of altered GnRH stimulatory and inhibitory neurotransmitters in hypothalamic-pituitary centre. This, we hypothesise, is responsible for the depression and anxiety-like mood disorders commonly seen in PCOS women.
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Pharmacokinetics and bioavailability of non-polar phytocomponents of Aloe vera gel and their role as an endocrine modulator in letrozole induced PCOS rat model
Background and aim: Polycystic ovary syndrome (PCOS), the most common endocrine disorder in women of reproductive age with an estimated prevalence of 5–10%, is one of the most common causes of female infertility. The therapeutic options for PCOS are limited. Thereby, traditional knowledge of Ayurveda has been exploited to identify an herbal therapeutic target for PCOS. Pharmacokinetic (PK) studies on bioactive constituents of herbal drugs provide valuable information on bio-transformed metabolites, dosage form, doses and potential herb–drug interactions. Thereby, the aim of the study was to study the pharmacokinetics and bioavailability of the non-polar phytocomponents of Aloe vera gel and their role as an endocrine modulator in PCOS pathology. Methodology: PCOS was induced in rat using letrozole and validated for structural and metabolic characteristics of PCOS. Blood and tissues (ovaries, adrenal, hypothalamus, pituitary, uterus and liver) were collected upto 48 h after petroleum ether extract of dried Aloe vera gel (1.0 g) were administered orally to rats. Metabolites of Phytosterols were identified using GC/MS and quantified using HPLC. Progesterone and estradiol were analysed using ELISA. Steroidogenic enzymes as well as important enzymes responsible for biotransformation were evaluated along with the toxicity parameters. Results: PCOS animals demonstrated altered estrus cyclicity, serum testosterone levels and oral glucose tolerance test profile when compared to controls. An increase in the estradiol (PP<0.05) were observed in the plasma after 24 h. Several phytosterols and their modified oxysterols were identified in the plasma and tissues which could be well-correlated with the functional changes observed in hormone profile. Conclusion: This study elucidates the bioavailability and functionality of phytosterols/oxysterols obtained from Aloe vera gel towards management of PCOS. This study will be helpful in identification of a naturally derived drug target and add to its economic viability at national and international level.
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Pharmacokinetics and bioavailability of non-polar phytocomponents of Aloe vera gel and their role as an endocrine modulator in letrozole induced PCOS rat model
Background and aim: Polycystic ovary syndrome (PCOS), the most common endocrine disorder in women of reproductive age with an estimated prevalence of 5–10%, is one of the most common causes of female infertility. The therapeutic options for PCOS are limited. Thereby, traditional knowledge of Ayurveda has been exploited to identify an herbal therapeutic target for PCOS. Pharmacokinetic (PK) studies on bioactive constituents of herbal drugs provide valuable information on bio-transformed metabolites, dosage form, doses and potential herb–drug interactions. Thereby, the aim of the study was to study the pharmacokinetics and bioavailability of the non-polar phytocomponents of Aloe vera gel and their role as an endocrine modulator in PCOS pathology. Methodology: PCOS was induced in rat using letrozole and validated for structural and metabolic characteristics of PCOS. Blood and tissues (ovaries, adrenal, hypothalamus, pituitary, uterus and liver) were collected upto 48 h after petroleum ether extract of dried Aloe vera gel (1.0 g) were administered orally to rats. Metabolites of Phytosterols were identified using GC/MS and quantified using HPLC. Progesterone and estradiol were analysed using ELISA. Steroidogenic enzymes as well as important enzymes responsible for biotransformation were evaluated along with the toxicity parameters. Results: PCOS animals demonstrated altered estrus cyclicity, serum testosterone levels and oral glucose tolerance test profile when compared to controls. An increase in the estradiol (PP<0.05) were observed in the plasma after 24 h. Several phytosterols and their modified oxysterols were identified in the plasma and tissues which could be well-correlated with the functional changes observed in hormone profile. Conclusion: This study elucidates the bioavailability and functionality of phytosterols/oxysterols obtained from Aloe vera gel towards management of PCOS. This study will be helpful in identification of a naturally derived drug target and add to its economic viability at national and international level.
- 29 October 2016
- Published by Walter de Gruyter GmbH in Hormone Molecular Biology and Clinical Investigation
- Vol. 29 (2) , 71-77
Neurotransmitter alteration in a testosterone propionate-induced polycystic ovarian syndrome rat model
Background: Polycystic ovarian syndrome (PCOS), one of the leading causes of infertility seen in women, is characterized by anovulation and hyperandrogenism, resulting in ovarian dysfunction. In addition, associations of several metabolic complications like insulin resistance, obesity, dyslipidemia and psychological co-morbidities are well known in PCOS. One of the major factors influencing mood and the emotional state of mind is neurotransmitters. Also, these neurotransmitters are very crucial for GnRH release. Hence, the current study investigates the status of neurotransmitters in PCOS. Materials and methods: A PCOS rat model was developed using testosterone. Twenty-one-day-old rats were subcutaneously injected with 10 mg/kg body weight of testosterone propionate (TP) for 35 days. The animals were validated for PCOS characteristics by monitoring estrus cyclicity, serum testosterone and estradiol levels and by histological examination of ovarian sections. Neurotransmitter estimation was carried out using fluorometric and spectrophotometric methods. Results: TP-treated animals demonstrated increased serum testosterone levels with unaltered estradiol content, disturbed estrus cyclicity and many peripheral cysts in the ovary compared to control rats mimicking human PCOS. Norepinephrine (NE), dopamine, serotonin, γ-amino butyric acid (GABA) and epinephrine levels were significantly low in TP-induced PCOS rats compared to control ones, whereas the activity of acetylcholinesterase in the PCOS brain was markedly elevated. Conclusion: Neurotransmitter alteration could be one of the reasons for disturbed gonadotropin-releasing hormone (GnRH) release, consequently directing the ovarian dysfunction in PCOS. Also, decrease in neurotransmitters, mainly NE, serotonin and dopamine (DA) attributes to mood disorders like depression and anxiety in PCOS.
- 29 October 2016
- Published by Walter de Gruyter GmbH in Hormone Molecular Biology and Clinical Investigation
- Vol. 29 (2) , 71-77
Neurotransmitter alteration in a testosterone propionate-induced polycystic ovarian syndrome rat model
Background: Polycystic ovarian syndrome (PCOS), one of the leading causes of infertility seen in women, is characterized by anovulation and hyperandrogenism, resulting in ovarian dysfunction. In addition, associations of several metabolic complications like insulin resistance, obesity, dyslipidemia and psychological co-morbidities are well known in PCOS. One of the major factors influencing mood and the emotional state of mind is neurotransmitters. Also, these neurotransmitters are very crucial for GnRH release. Hence, the current study investigates the status of neurotransmitters in PCOS. Materials and methods: A PCOS rat model was developed using testosterone. Twenty-one-day-old rats were subcutaneously injected with 10 mg/kg body weight of testosterone propionate (TP) for 35 days. The animals were validated for PCOS characteristics by monitoring estrus cyclicity, serum testosterone and estradiol levels and by histological examination of ovarian sections. Neurotransmitter estimation was carried out using fluorometric and spectrophotometric methods. Results: TP-treated animals demonstrated increased serum testosterone levels with unaltered estradiol content, disturbed estrus cyclicity and many peripheral cysts in the ovary compared to control rats mimicking human PCOS. Norepinephrine (NE), dopamine, serotonin, γ-amino butyric acid (GABA) and epinephrine levels were significantly low in TP-induced PCOS rats compared to control ones, whereas the activity of acetylcholinesterase in the PCOS brain was markedly elevated. Conclusion: Neurotransmitter alteration could be one of the reasons for disturbed gonadotropin-releasing hormone (GnRH) release, consequently directing the ovarian dysfunction in PCOS. Also, decrease in neurotransmitters, mainly NE, serotonin and dopamine (DA) attributes to mood disorders like depression and anxiety in PCOS.
- 1 May 2015
- Published by Bioscientifica in Endocrine Abstracts
Influence of neurotransmitters on GnRH release in letrozole induced PCOS rat model
Background: Polycystic ovarian syndrome (PCOS) is a common reproductive-endocrine disorder seen in women; characterized by increased GnRH pulsatility, hyperandrogenism, and cyst formation in ovary. GnRH release is controlled by higher centres of brain namely, hypothalamus and pituitary through various feedback mechanisms, one of them being neurotransmitters. However, no clear data is available with respect to GnRH regulation by neurotransmitters in PCOS. The aim of the present study was to evaluate status of neurotransmitters and their receptors in PCOS and to correlate this with GnRH pulsatility. Materials and methods: PCOS was induced in rats using letrozole – an aromatase inhibitor – and validated for structural and metabolic characteristics of PCOS. Neurotransmitters were estimated from different regions of rat brain by HPLC and detected electrochemically. RNA was isolated from hypothalamus and pituitary using TRIzol reagent and cDNA was synthesized by first strand cDNA synthesis kit. This cDNA was further used for real-time expression studies of gonadotropins and neurotransmitter receptors. Results: PCOS rats demonstrated increased hypothalamic GnRH1; pituitary GnRHR and LHβ mRNA levels as compared to control rats. Reduced levels of norepinephrine, dopamine, serotonin, γ-amino butyric acid, and epinephrine with increased glutamate levels were observed in pituitary and hypothalamus of PCOS rats as compared to control rats. Expression of neurotransmitter receptors – 5HT1A, GABAB1, D2R, and α1A receptor decreased while that of NMDA receptor increased in hypothalamus and pituitary of PCOS rats. Conclusion: Letrozole treated rat demonstrated hormonal and metabolic characteristics of PCOS with peripheral cysts in the ovary. Present study confirms that modulation in GnRH stimulatory as well as inhibitory neurotransmitters could have contributed to increased GnRH pulsatility, further resulting into increased LH to FSH ratio in PCOS.
- 1 May 2015
- Published by Bioscientifica in Endocrine Abstracts
Influence of neurotransmitters on GnRH release in letrozole induced PCOS rat model
Background: Polycystic ovarian syndrome (PCOS) is a common reproductive-endocrine disorder seen in women; characterized by increased GnRH pulsatility, hyperandrogenism, and cyst formation in ovary. GnRH release is controlled by higher centres of brain namely, hypothalamus and pituitary through various feedback mechanisms, one of them being neurotransmitters. However, no clear data is available with respect to GnRH regulation by neurotransmitters in PCOS. The aim of the present study was to evaluate status of neurotransmitters and their receptors in PCOS and to correlate this with GnRH pulsatility. Materials and methods: PCOS was induced in rats using letrozole – an aromatase inhibitor – and validated for structural and metabolic characteristics of PCOS. Neurotransmitters were estimated from different regions of rat brain by HPLC and detected electrochemically. RNA was isolated from hypothalamus and pituitary using TRIzol reagent and cDNA was synthesized by first strand cDNA synthesis kit. This cDNA was further used for real-time expression studies of gonadotropins and neurotransmitter receptors. Results: PCOS rats demonstrated increased hypothalamic GnRH1; pituitary GnRHR and LHβ mRNA levels as compared to control rats. Reduced levels of norepinephrine, dopamine, serotonin, γ-amino butyric acid, and epinephrine with increased glutamate levels were observed in pituitary and hypothalamus of PCOS rats as compared to control rats. Expression of neurotransmitter receptors – 5HT1A, GABAB1, D2R, and α1A receptor decreased while that of NMDA receptor increased in hypothalamus and pituitary of PCOS rats. Conclusion: Letrozole treated rat demonstrated hormonal and metabolic characteristics of PCOS with peripheral cysts in the ovary. Present study confirms that modulation in GnRH stimulatory as well as inhibitory neurotransmitters could have contributed to increased GnRH pulsatility, further resulting into increased LH to FSH ratio in PCOS.
- 1 May 2015
- Published by Bioscientifica in Endocrine Abstracts
Unravelling the role of stress regulators on GnRH release in Letrozole induced PCOS rat model
Background and aim: polycystic ovarian syndrome is a multi aetiological female endocrinopathy wherein one of the major target organs affected is adrenal. It is important to note that adrenal plays key role in evoking stress mediated responses in brain; which can in turn affect GnRH, the main regulator of HPG axis. Along with corticotrophin releasing factor (CRF), newly discovered neuropeptides- urocortin2 and RF-amide related peptide-3 (RFRP-3) (mammalian GnIH analogue) are also known to modulate stress. However, complex regulation of GnRH axis via stress regulatory molecules and gonadal function adaptations is not clear. Thereby, current study was undertaken to elucidate the interaction of stress regulators with GnRH in PCOS pathology. Material and methods: PCOS was induced in rat using letrozole-an aromatase inhibitor and confirmed for pathology. Hormones-gonadotropins, androgen, oestradiol, progesterone levels were measured by ELISA. Regulatory neurotransmitter-GABA was estimated by HPLC. Expression studies of GnRH regulatory neuropetides and their receptors- CRF1, CRFR1, Ucn2, CRFR2, GnRH, GnRHR, RFRP-3, GPR-147 were carried out using real-time PCR. Results: Hypothalamus and pituitary of PCOS rats demonstrated an increase in corticosterone (PPPPPP<0.05) with reduced GABAB1 receptor expression in PCOS rats. PCOS rats also showed significant alterations in mRNA expressions of Ucn2, RFRP-3 and GnRH1 with their receptors CRF2, GPR-147 and GnRHR, respectively. Conclusion: This study elucidates the complex regulation of GnRH in the hypothalamus and pituitary by stress elements- Ucn2, RFRP-3 and their involvement in altered GnRH release in PCOS pathology.
- 1 May 2015
- Published by Bioscientifica in Endocrine Abstracts
Unravelling the role of stress regulators on GnRH release in Letrozole induced PCOS rat model
Background and aim: polycystic ovarian syndrome is a multi aetiological female endocrinopathy wherein one of the major target organs affected is adrenal. It is important to note that adrenal plays key role in evoking stress mediated responses in brain; which can in turn affect GnRH, the main regulator of HPG axis. Along with corticotrophin releasing factor (CRF), newly discovered neuropeptides- urocortin2 and RF-amide related peptide-3 (RFRP-3) (mammalian GnIH analogue) are also known to modulate stress. However, complex regulation of GnRH axis via stress regulatory molecules and gonadal function adaptations is not clear. Thereby, current study was undertaken to elucidate the interaction of stress regulators with GnRH in PCOS pathology. Material and methods: PCOS was induced in rat using letrozole-an aromatase inhibitor and confirmed for pathology. Hormones-gonadotropins, androgen, oestradiol, progesterone levels were measured by ELISA. Regulatory neurotransmitter-GABA was estimated by HPLC. Expression studies of GnRH regulatory neuropetides and their receptors- CRF1, CRFR1, Ucn2, CRFR2, GnRH, GnRHR, RFRP-3, GPR-147 were carried out using real-time PCR. Results: Hypothalamus and pituitary of PCOS rats demonstrated an increase in corticosterone (PPPPPP<0.05) with reduced GABAB1 receptor expression in PCOS rats. PCOS rats also showed significant alterations in mRNA expressions of Ucn2, RFRP-3 and GnRH1 with their receptors CRF2, GPR-147 and GnRHR, respectively. Conclusion: This study elucidates the complex regulation of GnRH in the hypothalamus and pituitary by stress elements- Ucn2, RFRP-3 and their involvement in altered GnRH release in PCOS pathology.
- 1 May 2015
- Published by Bioscientifica in Endocrine Abstracts
Implication of non polar phytocomponents of aloe vera gel in management of polycystic ovarian syndrome
Background: Aloe vera gel has been proven to have hypoglycaemic, hypolipidemic, and steroid enzyme regulating properties. These are of clinical significance in reproductive pathology namely polycystic ovary syndrome (PCOS). Preliminary, ‘in-vitro’ studies suggested that non-polar component is responsible for the steroid enzyme modulating effect. This study investigates the role of non polar phytocomponent’s of aloe vera gel, which could be responsible in management of this pathology. Aim: The aim of this study was to evaluate the effects of non-polar phyto-components on the PCOS pathology using rodent model. Design and methods: Rodent model was developed using letrozole (0.5 g/kg body weight daily orally for 21 days) and validated for PCOS pathology. Later, the non-polar component, extracted using petroleum ether (containing phytosterols validated by HPTLC) was administered to PCOS rats daily (~25 μg/kg body weight) for 2 months, with respective controls (Aloe and vehicle). After the course of treatment, ovarian expression profile (mRNA and protein) of major steroidogenic genes namely StAR, 3 beta-hydroxysteroid dehydrogenase (3β-HSD), aromatase, LHR, and FSH-R were monitored in addition to biochemical parameters. Parallely, phytochemical elucidation of non-polar fraction was evaluated. Results: Expression of StAR, 3β-HSD, and LHR was found to be decreased (P<0.01), both at transcript as well as protein level in non-polar fraction treated PCOS group as compared with untreated PCOS control while other genes studied did not show any significant change. Phytochemically, aloe vera non-polar fraction exhibited the presence of β-sitosterol in major quantity, along with minor amounts of stigmasterol, lupeol, and its derivatives. Conclusion: Non-polar fraction of aloe vera gel has a potential to manage PCOS phenotype, by modifying steroidogenic targets. This study may serve as platform for designing drugs by exploring these novel targets. Disclosure: This work was supported partly by University Grants commision, India (F.no: 41-1276/2012(SR) and by Department of Science and Technology (SB/SO/HS-190/2013).
- 1 May 2015
- Published by Bioscientifica in Endocrine Abstracts
Implication of non polar phytocomponents of aloe vera gel in management of polycystic ovarian syndrome
Background: Aloe vera gel has been proven to have hypoglycaemic, hypolipidemic, and steroid enzyme regulating properties. These are of clinical significance in reproductive pathology namely polycystic ovary syndrome (PCOS). Preliminary, ‘in-vitro’ studies suggested that non-polar component is responsible for the steroid enzyme modulating effect. This study investigates the role of non polar phytocomponent’s of aloe vera gel, which could be responsible in management of this pathology. Aim: The aim of this study was to evaluate the effects of non-polar phyto-components on the PCOS pathology using rodent model. Design and methods: Rodent model was developed using letrozole (0.5 g/kg body weight daily orally for 21 days) and validated for PCOS pathology. Later, the non-polar component, extracted using petroleum ether (containing phytosterols validated by HPTLC) was administered to PCOS rats daily (~25 μg/kg body weight) for 2 months, with respective controls (Aloe and vehicle). After the course of treatment, ovarian expression profile (mRNA and protein) of major steroidogenic genes namely StAR, 3 beta-hydroxysteroid dehydrogenase (3β-HSD), aromatase, LHR, and FSH-R were monitored in addition to biochemical parameters. Parallely, phytochemical elucidation of non-polar fraction was evaluated. Results: Expression of StAR, 3β-HSD, and LHR was found to be decreased (P<0.01), both at transcript as well as protein level in non-polar fraction treated PCOS group as compared with untreated PCOS control while other genes studied did not show any significant change. Phytochemically, aloe vera non-polar fraction exhibited the presence of β-sitosterol in major quantity, along with minor amounts of stigmasterol, lupeol, and its derivatives. Conclusion: Non-polar fraction of aloe vera gel has a potential to manage PCOS phenotype, by modifying steroidogenic targets. This study may serve as platform for designing drugs by exploring these novel targets. Disclosure: This work was supported partly by University Grants commision, India (F.no: 41-1276/2012(SR) and by Department of Science and Technology (SB/SO/HS-190/2013).
- 14 January 2015
- Published by Springer Nature in Current Microbiology
- Vol. 70 (5) , 690-697
Protection Against 1,2-Di-methylhydrazine-Induced Systemic Oxidative Stress and Altered Brain Neurotransmitter Status by Probiotic Escherichia coli CFR 16 Secreting Pyrroloquinoline Quinone
Exposure to environmental pollutant 1,2-dimethylhydrazine (DMH) is attributed to systemic oxidative stress and is known to cause neurotropic effect by altering brain neurotransmitter status. Probiotics are opted as natural therapeutic against oxidative stress and also have the ability to modulate gut–brain axis. Pyrroloquinoline quinone (PQQ) is water-soluble, heat-stable antioxidant molecule. Aim of the present study was to evaluate the antioxidant efficacy of PQQ-producing probiotic E. coli CFR 16 on DMH-induced systemic oxidative damage and altered neurotransmitter status in rat brain. Adult virgin Charles Forster rats (200–250 g) were given DMH dose (25 mg/kg body weight, s.c.) for 8 weeks. Blood lipid peroxidation levels exhibited a marked increase while antioxidant enzyme activities of superoxide dismutase, catalase, glucose-6-phosphate dehydrogenase and glutathione peroxidase were found to be reduced in DMH-treated rats. Likewise, brain serotonin and norepinephrine levels displayed a significant decrease, whereas epinephrine levels demonstrated a marked increase in brain of these rats. PQQ-producing E. coli CFR 16 supplementation reduced systemic oxidative stress and also restored brain neurotransmitter status. However, E. coli CFR 16 did not show any effect on these parameters. In contrast, E. coli CFR 16:: vgb–gfp and E. coli CFR 16:: vgb–gfp vector exhibited some degree of protection again oxidative stress but they were not able to modulate neurotransmitter levels. In conclusion, continuous and sustained release of PQQ by probiotic E. coli in rat intestine ameliorates systemic oxidative stress and restored brain neurotransmitter levels.
- 14 January 2015
- Published by Springer Nature in Current Microbiology
- Vol. 70 (5) , 690-697
Protection Against 1,2-Di-methylhydrazine-Induced Systemic Oxidative Stress and Altered Brain Neurotransmitter Status by Probiotic Escherichia coli CFR 16 Secreting Pyrroloquinoline Quinone
Exposure to environmental pollutant 1,2-dimethylhydrazine (DMH) is attributed to systemic oxidative stress and is known to cause neurotropic effect by altering brain neurotransmitter status. Probiotics are opted as natural therapeutic against oxidative stress and also have the ability to modulate gut–brain axis. Pyrroloquinoline quinone (PQQ) is water-soluble, heat-stable antioxidant molecule. Aim of the present study was to evaluate the antioxidant efficacy of PQQ-producing probiotic E. coli CFR 16 on DMH-induced systemic oxidative damage and altered neurotransmitter status in rat brain. Adult virgin Charles Forster rats (200–250 g) were given DMH dose (25 mg/kg body weight, s.c.) for 8 weeks. Blood lipid peroxidation levels exhibited a marked increase while antioxidant enzyme activities of superoxide dismutase, catalase, glucose-6-phosphate dehydrogenase and glutathione peroxidase were found to be reduced in DMH-treated rats. Likewise, brain serotonin and norepinephrine levels displayed a significant decrease, whereas epinephrine levels demonstrated a marked increase in brain of these rats. PQQ-producing E. coli CFR 16 supplementation reduced systemic oxidative stress and also restored brain neurotransmitter status. However, E. coli CFR 16 did not show any effect on these parameters. In contrast, E. coli CFR 16:: vgb–gfp and E. coli CFR 16:: vgb–gfp vector exhibited some degree of protection again oxidative stress but they were not able to modulate neurotransmitter levels. In conclusion, continuous and sustained release of PQQ by probiotic E. coli in rat intestine ameliorates systemic oxidative stress and restored brain neurotransmitter levels.
- Top Cited PapersOpen Access
- 1 January 2015
- Published by Elsevier in Journal of Traditional and Complementary Medicine
- Vol. 5 (1) , 21-26
Evaluation of biological properties and clinical effectiveness of Aloe vera: A systematic review
- 1 January 2015
- Published by Elsevier in Journal of Traditional and Complementary Medicine
- Vol. 5 (1) , 21-26
Top Cited PapersOpen AccessEvaluation of biological properties and clinical effectiveness of Aloe vera: A systematic review